Glycogene Discovery Service in Thyroid Cancer

Glycogene Discovery Service in Thyroid Cancer

Thyroid Cancer and Glycosylation

Thyroid cancer is the most common malignant tumor of the endocrine system, and its incidence has increased significantly in the past 40 years. Studies have shown that glycogen metabolism plays an oncogenic role in multiple tumor types. Glycogen genes and enzymes may be expressed in normal thyroid and thyroid cancer cells based on RNA-sequencing data of anaplastic thyroid cancer (ATC) cells. Therefore, glycans and cancer biomarkers based on aberrantly glycosylated proteins have gained increasing recognition. Most tumor biomarkers currently used clinically are glycoproteins. Aberrant glycosylation has been identified as a hallmark of cancer. Meanwhile, it offered a new view of cancer research involving underlying mechanisms of investigation and clinical translation and application.

Fig.1 Glycolysis and glycogen metabolism. (Davidson & Carr, 2021)Fig.1 Glycolysis and glycogen metabolism. (Davidson & Carr, 2021)

Glycogene Discovery Service in Thyroid Cancer

With constant collaboration and innovation over the years, CD BioGlyco is a professional cancer glycogene discovery servicer with strong scientific research capabilities and an advanced technology platform. We formulate different programs to meet the needs of clients to ensure that we provide the best service for different projects.

  • Discovery methods
    • Next-generation sequencing (NGS) transcriptome analysis: To measure the expression levels of glycogenes to uncover differences in the expression of glycoproteins between normal and cancer cells.
    • Immunohistochemistry and the quantitative real-time polymerase chain reaction (qRT-PCR): To detect the expression of the protein in normal and cancer tissues.
    • Bioinformatics analysis: To identify the glycosylation-related genes.
    • Glycoproteomics techniques: mass spectrometry (MS)
    • Systematic transcriptomic analysis: To identify the gene signature for glycogene-type classification.
    • Capture of specific glycan of the glycoproteins: Lectin-based technologies: Lectin Affinity Chromatography and lectin microarray
  • Summary of glycogenes involved in thyroid cancer
    • Fucosyltransferase 8 (FUT8)
    • GnT-V N-acetylglucosaminyltransferase-V (GnT-V)
    • Glypican 3 (GPC3)
    • Glycogen synthase and glycogen phosphorylase (PYG) isoforms

Fig.2 Glycogene discovery in thyroid cancer. (CD BioGlyco)Fig.2 Glycogene discovery in thyroid cancer. (CD BioGlyco)


  • Glycosylation provides a novel view for therapeutic target prediction and clinical decision-making.
  • Clarify the scientific research application and clinical application of biomarkers in the field of study of cancer, to better serve patients.
  • Our service helps to understand the relationship between aberrant glycosylation and carcinogenesis, and accelerating biomarker recognition and quantitative detection.


  • Professional advice from our analysis scientists.
  • Combination of multiple advanced analysis platforms.
  • Fast, customized, and reliable service.
  • Advanced instruments and experienced scientists.

CD BioGlyco is committed to providing first-class Cancer Glycogene Discovery Services. We have professional team management and a high-quality R&D team. Besides cancer glycogene discovery, we also provide Glycogene Editing Services and Glycogene Delivery Services. If you are interested in our service, please feel free to contact us at any time.


  1. Davidson, C.D.; Carr, F.E. Review of pharmacological inhibition of thyroid cancer metabolism. J Cancer Metastasis Treat. 2021, 7(45): 1-19.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.